Education
About Us
Working with TipRanks
Follow Us
Roche Holding Ltd (CH:RO)
:RO
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
10.64Last Year’s EPS
10.23Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 30, 2025
|% Change Since: 8.08%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
Roche Group's 2024 performance was marked by strong sales growth across its pharmaceutical and diagnostics divisions, significant margin expansion, and strong free cash flow. Key advancements in the pipeline and strategic acquisitions in diagnostics and pharmaceuticals support future growth. However, challenges in the China market and impairments affecting IFRS net income were notable concerns.Company Guidance
In the 2024 fiscal year, Roche Group achieved a strong performance, with a Group sales growth of 7% and an impressive 9% increase in the base business, excluding COVID-19 impacts. The pharmaceutical division noted a 9% growth, while diagnostics grew by 8%. The company successfully navigated the final COVID-19 sales reduction of CHF1.1 billion, aligned with its initial guidance, and managed an LOE impact slightly better than expected at CHF1 billion. Additionally, Roche's core operating profit rose by 14%, while its Group core operating margin improved by 2.1 percentage points. Core EPS also grew by 12% when excluding tax effects, and operating free cash flow surged by 34% to CHF21.2 billion. Looking forward, Roche anticipates a significant year in 2025 with numerous Phase III readouts and enabling studies, alongside continued strategic investments and expansion plans, particularly in diagnostics and oncology.Strong Overall Sales Growth
Group sales increased by 7%, with the base business excluding COVID-19 growing by 9%. Pharmaceuticals grew by 9% and diagnostics by 8%.
Core Operating Profit and Margin Expansion
Core operating profit grew by 14%, and the group core operating margin increased by 2.1 percentage points.
Strong Cash Flow Performance
Operating free cash flow increased by 34% to CHF 21.2 billion.
Pharmaceuticals Pipeline Progress
17 medicines achieved blockbuster status, with major advancements in oncology, neurology, and immunology.
Dividend Increase
Dividend increased for the 38th consecutive year.
Significant Diagnostics Innovations
Launch of cobas Mass Spec system and expansion of the Roche Digital Pathology platform.
---
CH:RO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CH:RO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | CHF299.40 | CHF304.00 | +1.54% |
| Jul 25, 2024 | CHF296.40 | CHF305.00 | +2.90% |
| Feb 01, 2024 | CHF251.93 | CHF237.69 | -5.65% |
| Jul 27, 2023 | CHF279.84 | CHF280.22 | +0.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roche Holding Ltd (CH:RO) report earnings?
Roche Holding Ltd (CH:RO) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Roche Holding Ltd (CH:RO) earnings time?
Roche Holding Ltd (CH:RO) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Roche Holding Ltd stock?
The P/E ratio of Roche Holding Ltd is N/A.
What is CH:RO EPS forecast?
CH:RO EPS forecast for the fiscal quarter 2025 (Q2) is 10.64.
---